CR1 and myeloid sarcoma: For the primary analysis, we used an additive model to assess whether the following late onset AD-associated variants influence brain atrophy and cognitive dysfunction in MS patients: PICALM (rs3851179), CR1 (rs6656401), CLU (rs11136000), PCK1 (rs8192708), and ZNF224 (rs3746319).